← Human Trials & Peer-Reviewed Studies
Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study
Plain-language guide to PMID 28340044 (2018): double-blind randomized controlled trial study of MK-677 (Ibutamoren) and IGF-1 LR3 in 26 subjects.
Key Facts
- PMID
- 28340044
- Journal
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Campbell GA et al. (5 authors)
- DOI
- 10.1093/ndt/gfw474
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of MK-677 (Ibutamoren) and IGF-1 LR3, published as a randomized controlled trial.
Who Took Part
According to the abstract, 26 subjects were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
The researchers performed a randomized crossover double-blind study in assessing the effect of MK-0677 versus placebo on IGF-1 levels, the primary outcome, in hemodialysis patients.
In total, 26 subjects enrolled and 22 completed the 3-month crossover study.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
The subjects were allocated by chance, so the MK-677 (Ibutamoren) group and the comparison group should start out alike.
Blinding on both sides kept the subjects and researchers unaware of who received MK-677 (Ibutamoren).
Some subjects received a placebo instead of MK-677 (Ibutamoren), giving a reference point.
In the crossover set-up each of the subjects took both MK-677 (Ibutamoren) and the comparison in turn, acting as their own control.
What Was Measured
The subject headings attached to it are Indoles, Insulin-Like Growth Factor I, Kidney Failure, Chronic, Prognosis, Quality of Life, Receptors, Ghrelin and Renal Dialysis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of MK-677 (Ibutamoren) and IGF-1 LR3 in 26 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.
More context: the MK-677 (Ibutamoren) compound page and the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compounds
MK-677 (Ibutamoren): An oral, non-peptide ghrelin-receptor agonist.
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.